Stay updated with breaking news from Rare Head. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A large, multi-institutional study demonstrates that a blood test to detect circulating tumor DNA can accurately predict recurrence of HPV-driven oropharyngeal cancer following treatment.
A blood test to detect circulating tumor DNA accurately predicted recurrence of HPV-driven oropharyngeal cancer after treatment, according to research presented at Multidisciplinary Head and Neck Cancers Symposium.In addition, findings from the retrospective clinical case series suggested the biomarker test may detect disease recurrence earlier than imaging or other surveillance methods, allowing
Press release content from Business Wire. The AP news staff was not involved in its creation. Repertoire Immune Medicines and Dana-Farber Cancer Institute Collaborate to Identify Novel Antigen Targets Within HPV+ Head and Neck Cancers February 11, 2021 GMT Anthony Coyle, Ph.D., President, Research and Development, Repertoire Immune Medicines (Photo: Business Wire) CAMBRIDGE, Mass.--(BUSINESS WIRE)--Feb 11, 2021-- Repertoire Immune Medicines, a clinical-stage biotech company creating a new category of immune therapies for cancer, autoimmunity and infectious disease, today announced a research ...